The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any pr...
Mabion S.A., a Polish biotechnology company, has signed a letter of intent (LoI) with French TechDev company Oddifact SAS to evaluate and advance...
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes Accelerat...
New registry will generate robust real-world evidence on disease burden, treatment patterns and long-term effectiveness of newly approved and emerging th...
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a...
Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory dise...
Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, announced th...
As drug development becomes increasingly complex, early-phase clinical trials are taking on a far more strategic role than simply establish...
As real-world evidence assumes a growing role in oncology research, regulatory evaluation, and clinical decision-making, the quality of underlying data has...
Aragen, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully tech-transferred and manufactured the fir...
In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, no longer meeting...
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agon...
As oncology care becomes increasingly personalized and technology-enabled, digital tools are playing a growing role in improving patient outcomes beyond th...
ADC Therapeutics SA announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in co...
© 2026 Biopharma Boardroom. All Rights Reserved.
